New ‘peptoids’ show promise in resistant prostate cancer
A new generation of anti-androgen drugs such as Pfizer and Astellas’ Xtandi and Johnson & Johnson’s Zytiga have increased survival... Read More
Sophiris Stops Additional Doses in Topsalysin Prostate Cancer Trial Following Patient Death
Sophiris Bio has halted additional doses in an open-label study of topsalysin in prostate cancer, as it investigates the death... Read More
Testing for 63 Gene Variants Identifies Elevated Risk for Prostate Cancer
A transatlantic team of scientists led by the London-based Institute of Cancer Research (ICR) has made a major step towards... Read More
Dendreon Eyes Real-World Data Boost for Lagging Prostate Cancer Med Provenge
Years after winning a hotly anticipated FDA approval for its cancer immunotherapy Provenge—and struggling to build sales of the prostate... Read More
Myriad Touts 10-Year Data for Prostate Cancer Screen
Myriad Genetics unveiled new data showing its prostate cancer diagnostic could accurately predict the 10-year risk of metastasis in men... Read More
Researchers Create Test to Predict Response to Xtandi, Zytiga
Researchers have created a $65 test designed to show which prostate cancer patients will respond to Pfizer’s Xtandi and Johnson... Read More
Newly Discovered Genetic Fngerprint for Prostate Cancer Promises to Personalize Treatment
Scientists at the University of Toronto have discovered a set of genetic mutations that they believe will help oncologists predict when... Read More